Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: CMS’s price reveal better than expected?; new diabetes risk data for Zepbound; can J&J’s lung cancer combo stand up to Tagrisso?; new recruits for BioMarin leadership; and Glenmark’s shifting revenues.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 23 August 2024, including: CMS’s price reveal better than expected?; new diabetes risk data for Zepbound; can J&J’s lung cancer combo stand up to Tagrisso?; new recruits for BioMarin Pharmaceutical Inc. leadership; and Glenmark Pharmaceuticals Limited’s shifting revenues.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "CMS’s Big Drug Price Reveal Turns Out Better For Pharma Than Feared" - Scrip, 15 Aug, 2024.)
(Also see "Lilly Data Show Zepbound Reduces Type 2 Diabetes Risk Long Term" - Scrip, 20 Aug, 2024.)
(Also see "Can J&J’s Rybrevant/Lazcluze Combo Stand Up To Tagrisso?" - Scrip, 20 Aug, 2024.)
(Also see "BioMarin Recruits Amgen R&D’s Friberg, Roche Dealmaker Sabry To Leadership Team" - Scrip, 21 Aug, 2024.)
(Also see "Glenmark Chief On ‘Big Shift’ In Revenue By Region, Liraglutide India Outlook" - Scrip, 21 Aug, 2024.)